美国银行将蓝鸟生物库存降级为“Neutral”, 反映了生物技术的金融斗争。 Bank of America downgrades Bluebird bio's stock to "Neutral," reflecting the biotech's financial struggles.

美国银行将蓝鸟生物库存从“Buy”降为“Neutral”,将目标价格降至0.50美元。 Bank of America downgraded Bluebird bio's stock from "Buy" to "Neutral," lowering the target price to $0.50. 开发严重遗传疾病基因疗法的生物技术公司得到分析家的好坏参半的评级。 The biotech company, which develops gene therapies for severe genetic diseases, has seen mixed ratings from analysts. 尽管最近被降级, 某些像巴克莱人一样的人 仍然把它评为“超重”。 Despite recent downgrades, some like Barclays still rate it "Overweight." 蓝鸟生物存量下降到0.32美元,反映了负财政指标,如567.29%的负净差。 Bluebird bio's stock fell to $0.32, reflecting negative financial metrics like a 567.29% negative net margin. 机构投资者增加了对该公司的股份。 Institutional investors have increased their stakes in the company.